Herantis Pharma Oyj (HEL:HRTIS)

Finland flag Finland · Delayed Price · Currency is EUR
1.930
-0.010 (-0.52%)
Aug 13, 2025, 6:29 PM EET
35.92%
Market Cap 46.74M
Revenue (ttm) n/a
Net Income (ttm) -4.94M
Shares Out 24.09M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 24,142
Average Volume 48,503
Open 1.930
Previous Close 1.940
Day's Range 1.860 - 1.930
52-Week Range 1.180 - 2.020
Beta 0.24
RSI 70.94
Earnings Date Aug 21, 2025

About Herantis Pharma Oyj

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 11
Stock Exchange Nasdaq Helsinki
Ticker Symbol HRTIS
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.